Protara Therapeutics, Inc. (TARA)

Protara Therapeutics' stock has experienced fluctuations due to clinical trial progress and financial updates. Positive interim results from the Phase 2 STARBORN-1 trial of TARA-002 in pediatric patients with lymphatic malformations and the ADVANCED-2 trial of TARA-002 in NMIBC patients led to investor optimism. The company's Q3 2025 earnings beat analysts' estimates, and Q2 2025 results highlighted increased R&D expenses but confirmed sufficient cash reserves. Analysts have given the company an average recommendation of "Moderate Buy" or "Strong Buy". Protara Therapeutics was added to the Russell 3000® Index in June 2025.

Information regarding specific demand seasonality for Protara Therapeutics is not readily available. Demand for its investigational products is primarily driven by clinical trial progress, regulatory milestones, and the prevalence of the diseases they aim to treat, rather than typical seasonal consumer patterns.

Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases. Their pipeline includes TARA-002, a cell-based therapy in Phase II trials for NMIBC and LMs, and IV choline chloride, an investigational therapy for IFALD in patients receiving parenteral nutrition.

Protara Therapeutics is headquartered in New York, NY, and has a manufacturing agreement with Chugai Pharmaceutical Co., Ltd. for commercial picibanil from a facility in Winston-Salem, NC, indicating a manufacturing presence in the U.S. and potential market reach into Japan.

Protara Therapeutics has maintained a positive brand reputation, particularly among financial analysts, who have given the company an average rating of "Moderate Buy" or "Strong Buy". This positive sentiment is driven by promising clinical trial results for its lead product candidates, TARA-002 and IV choline chloride. There have been no significant public events reported in the past year that have negatively impacted Protara Therapeutics' brand reputation.

Institutional investors hold a significant portion of Protara Therapeutics' stock, owning approximately 38.13% to 71% of the company's shares. Major institutional shareholders include Janus Henderson Group Plc, BlackRock, Inc., Velan Capital Investment Management LP, Blackstone Group Inc, Vanguard Group Inc, Acorn Capital Advisors, Llc, Catalio Capital Management, LP, Integral Health Asset Management, LLC, and UBS Group AG. Individual investors hold around 11% to 54.55% of the stock, while insiders own approximately 4.11%.